1991
DOI: 10.1016/0005-2760(91)90052-j
|View full text |Cite
|
Sign up to set email alerts
|

A two component-type cytochrome P-450 monooxygenase system in a prokaryote that catalyzes hydroxylation of ML-236B to pravastatin, a tissue-selective inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
24
0

Year Published

2001
2001
2019
2019

Publication Types

Select...
7
3

Relationship

0
10

Authors

Journals

citations
Cited by 59 publications
(24 citation statements)
references
References 15 publications
0
24
0
Order By: Relevance
“…Crespi et al (11) also reported the presence of a ferredoxin-like domain at the N terminus of a protein otherwise dissimilar to any protein involved in P450 reactions. A twocomponent bacterial cytochrome P450 system was reported by Serizawa and Matsuoka (38), with the reductase component containing both FAD and FMN groups and no ferredoxin being required for activity. A gene, xplB, with homology to adrenodoxin reductase, is found 62 bp upstream of xplA.…”
Section: Discussionmentioning
confidence: 99%
“…Crespi et al (11) also reported the presence of a ferredoxin-like domain at the N terminus of a protein otherwise dissimilar to any protein involved in P450 reactions. A twocomponent bacterial cytochrome P450 system was reported by Serizawa and Matsuoka (38), with the reductase component containing both FAD and FMN groups and no ferredoxin being required for activity. A gene, xplB, with homology to adrenodoxin reductase, is found 62 bp upstream of xplA.…”
Section: Discussionmentioning
confidence: 99%
“…38 Although simvastatin is usually made from lovastatin chemically in a multistep process, an enzymatic/bioconversion process using recombinant Escherichia coli has been developed. 39 Another statin, pravastatin (Pravacol) ($3.6 billion in sales per year), is made via different biotransformation processes from compactin by Streptomyces carbophilus 40 and Actinomadura sp. 41 Both simvastatin and pravastatin are synthetic variants of the naturally occurring lovastatin and compactin.…”
Section: Anti-rejection Drugs (Agents That Suppress the Immune System)mentioning
confidence: 99%
“…A number of MCMOs play important roles as biocatalysts in commercially important biotechnological applications. This includes the hydroxylase from Streptomyces carbophilus SANK 62585 employed for the bioconversion of mevastatin into the widely used hypocholestemic drug pravastatin (Matsuoka et al 1989;Serizawa and Matsuoka 1991) and a number of luciferases exploited both directly and indirectly in various applications due to their characteristic bioluminescent properties (Hastings et al 1985;Meighen 1991).…”
Section: Introductionmentioning
confidence: 99%